{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:04:17Z","timestamp":1774339457274,"version":"3.50.1"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"11","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age.<\/jats:p><jats:p>\n          Objective\u2003To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment.<\/jats:p><jats:p>\n          Methods\u2003A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM.<\/jats:p><jats:p>\n          Results\u2003After 3 months of LCM administration, in 73.1% of the children, there was a reduction of\u2009&gt;\u200950% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers.<\/jats:p><jats:p>\n          Conclusions\u2003Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures.<\/jats:p>","DOI":"10.1055\/s-0042-1758366","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T23:35:12Z","timestamp":1672270512000},"page":"1090-1096","source":"Crossref","is-referenced-by-count":8,"title":["Use of lacosamide in children: experience of a tertiary medical care center in Brazil"],"prefix":"10.1055","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9930-9002","authenticated-orcid":false,"given":"Tayla Taynan","family":"Rom\u00e3o","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Faculdade de Medicina, Departamento de Neurologia, Niter\u00f3i RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-9062","authenticated-orcid":false,"given":"Abra\u00e3o Iuri Medeiros","family":"Angelim","sequence":"additional","affiliation":[{"name":"Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9641-9831","authenticated-orcid":false,"given":"Henrique Jannuzzelli Pires do","family":"Prado","sequence":"additional","affiliation":[{"name":"Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-0631","authenticated-orcid":false,"given":"Fernanda Veiga de","family":"Goes","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Sa\u00fade da Mulher, da Crian\u00e7a e do Adolescente Fernandes Figueira, Departamento de Neurologia, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-7434","authenticated-orcid":false,"given":"Maria Elisa Paiva","family":"Pires","sequence":"additional","affiliation":[{"name":"Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-6850","authenticated-orcid":false,"given":"Rosiane da Silva","family":"Fontana","sequence":"additional","affiliation":[{"name":"Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-0558","authenticated-orcid":false,"given":"Lais de Carvalho","family":"Pires","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Sa\u00fade da Mulher, da Crian\u00e7a e do Adolescente Fernandes Figueira, Departamento de Neurologia, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-265X","authenticated-orcid":false,"given":"Alexandre Ribeiro","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Faculdade de Medicina, Departamento de Neurologia, Niter\u00f3i RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-6849","authenticated-orcid":false,"given":"Isabella","family":"D'Andrea-Meira","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Faculdade de Medicina, Departamento de Neurologia, Niter\u00f3i RJ, Brazil."},{"name":"Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"S L Mosh\u00e9","year":"2015","journal-title":"Lancet"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17425255.2019.1575361","article-title":"Pharmacokinetic considerations for anti-epileptic drugs in children","volume":"15","author":"A Verrotti","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"P Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","article-title":"Preliminary efficacy and safety of lacosamide in children with refractory epilepsy","volume":"16","author":"E Heyman","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"F Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pediatrneurol.2010.12.003","article-title":"Experience with lacosamide in a series of children with drug-resistant focal epilepsy","volume":"44","author":"L M Guilhoto","year":"2011","journal-title":"Pediatr Neurol"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0883073812436741","article-title":"Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study","volume":"27","author":"R G Rastogi","year":"2012","journal-title":"J Child Neurol"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"E McGinnis","year":"2016","journal-title":"Epilepsia"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"S Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0883073812462887","article-title":"Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy","volume":"29","author":"W R Yorns Jr","year":"2014","journal-title":"J Child Neurol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"I E Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"E Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial","volume":"50","author":"P Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"S Chung","year":"2010","journal-title":"Epilepsia"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000008126","article-title":"Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures","volume":"93","author":"V Farkas","year":"2019","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2020.04.016","article-title":"Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East","volume":"79","author":"G Hmaimess","year":"2020","journal-title":"Seizure"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40263-018-0523-7","article-title":"Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy","volume":"32","author":"S M Hoy","year":"2018","journal-title":"CNS Drugs"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.seizure.2018.01.014","article-title":"Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review","volume":"56","author":"J S Ortiz de la Rosa","year":"2018","journal-title":"Seizure"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/epi.13224","article-title":"A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study","volume":"56","author":"U Runge","year":"2015","journal-title":"Epilepsia"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: comparison of efficacy and safety","volume":"22","author":"A Verrotti","year":"2013","journal-title":"Seizure"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide","volume":"29","author":"V Villanueva","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"J K Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","article-title":"Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy","volume":"125","author":"S M Sisodiya","year":"2002","journal-title":"Brain"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13318-012-0093-x","article-title":"Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration","volume":"37","author":"W Cawello","year":"2012","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/epi.13502","article-title":"Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial","volume":"57","author":"D G Vossler","year":"2016","journal-title":"Epilepsia"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:01:15Z","timestamp":1683244875000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,12,28]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758366","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}